Mark Gottlieb
@Altium Capital Management Lp
Latest period2024 - Q3ReportedManaged Assets$339.708MTotal holdings77
Assets growth rate-99.86%Assets growth rate (2-Q avg)-51.42%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Altium Capital Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 77 positions.
Assets under management
The assets under management (AUM) of Altium Capital Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 339.708M in assets, with a quarterly growth rate of -99.86% and a 2-quarter average growth rate of -51.42%. The portfolio is managed by Mark Gottlieb, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
VERAVera Therapeutics Inc
| 8.9% | $30.233M 684,000 shares@ $44.2 avg price | Decreased -4.2% |
ADMAAdma Biologics Inc
| 8.01% | $27.186M 1.36M shares@ $19.99 avg price | Decreased -9.93% |
SRPTSarepta Therapeutics Inc
| 6.25% | $21.231M 170,000 shares@ $124.89 avg price | Increased 107.58% |
EWEdwards Lifesciences Corp
| 4.32% | $14.65M 222,000 shares@ $65.99 avg price | New Position |
XENEXenon Pharmaceuticals Inc
| 4.29% | $14.567M 370,000 shares@ $39.37 avg price | Increased 2.61% |
ZVRAZevra Therapeutics Inc
| 3.48% | $11.798M 1.7M shares@ $6.94 avg price | Increased 46.25% |
ITCIIntra-cellular Therapies Inc
| 3.32% | $11.268M 154,000 shares@ $73.17 avg price | Decreased -20.2% |
SLNOSoleno Therapeutics Inc
| 3.17% | $10.75M 212,909 shares@ $50.49 avg price | |
GKOSGlaukos Corp
| 2.96% | $10.032M 77,000 shares@ $130.28 avg price | New Position |
INSMInsmed Inc
| 2.8% | $9.49M 130,000 shares@ $73.0 avg price | Decreased -31.57% |